Compare ADMA Biologics Inc (ADMA) vs Main Street Capital Corporation (MAIN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Main Street Capital Corporation — how do they compare? ADMA Biologics Inc trades at $9.81 (market cap $2.18B), while Main Street Capital Corporation trades at $58.95 (market cap $5.47B). The key difference: Main Street Capital Corporation is far larger — about 2.5× ADMA Biologics Inc's market cap, and Main Street Capital Corporation pays a 5.43% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | MAIN | |
|---|---|---|
Market Cap | $2.18B | $5.47B |
Sector | Health | Financials |
52-Week High | $20.38 | $67.54 |
52-Week Low | $7.60 | $49.63 |
Enterprise Value | $2.25B | — |
Dividend Yield | — | 5.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.
Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.
Main Street Capital (MAIN) trades at $58.94, up 3.79% with strong technical momentum. The stock shows bullish technical signals with support at $57 and resistance at $60. Recent Q2 2026 earnings beat expectations at $0.97 per share, though Q1 missed. The company maintains an 80.77% net income margin with consistent dividend payments, positioning it as a reliable income stock. Revenue trends show slight moderation from 2024's peak but remain above 2022-2023 levels.
Outlook remains positive given MAIN's strong profitability and dividend consistency, though near-term risks include expense pressures impacting earnings coverage and broader market volatility. Analyst consensus leans cautious with 78.57% hold ratings, suggesting limited upside from current levels despite the stock's technical strength and income appeal.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Main Street Capital Corporation
Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancings and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants and other securities of the lower middle market and middle market companies based in the US. Business is functioned through the U.S region and it derives the majority of the income from the source of fee, commission, and interest.
Read more on MAIN →
